Advancing Cancer Therapy Through Next-Generation Preclinical Models
- Leveraging patient-derived organoids (PDOs) and genetically engineered mouse model (GEMM)-derived organoids to enhance the predictive power of cancer immunotherapy studies
- Overcoming technical and biological hurdles in the development of relevant advanced stage and metastatic mouse models to better mimic human disease progression
- Integrating experimental biology with computational modelling to align preclinical outputs with clinical datasets, facilitating the creation of predictive in silico frameworks for translational oncology